BLOG / 🇮🇳 India / index intelligence · · daily

BSE Pharma Sector Regulatory Filings — November 13, 2026

India BSE PHARMA

By Gunpowder Editorial ·

3 medium priority 3 total filings analysed

Executive Summary

The India BSE PHARMA digest for 13 November 2026 captures a sector bifurcation: Divi's Laboratories delivered a standout Q2 FY27 with 32% YoY revenue growth and 64% PAT growth, while Alkem Laboratories reported revenue growth of ~13.8% but a 11.7% YoY decline in PAT, highlighting divergent earnings trajectories within the index.

Divi's growth was powered by custom synthesis (62% of H1 sales, ~50% YoY growth), but operating cash flow halved to ₹959 crores due to a ₹1,197 crore working capital build in inventory, signaling a capex-heavy phase. Alkem's margin pressure is evident with EPS falling to ₹56.48 from ₹63.99 and total comprehensive income down 17.4% YoY, despite PBT rising 11.6% due to exceptional items. Mankind Pharma's filing is purely administrative (RTA office relocation) with no financial impact, but it serves as a reminder of routine compliance. Across the three filings, no insider trading activity was disclosed, and no forward-looking guidance was provided, limiting catalyst visibility. The key theme is operational execution vs. working capital strain, with Divi's strong top-line offset by cash flow concerns and Alkem's profitability erosion despite revenue growth.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Tracking the trend? Catch up on the prior BSE Pharma Sector Regulatory Filings digest from November 05, 2026.

Investment Signals (9)

  • Revenue surged 32% YoY to ₹3,770 crores in Q2 FY27, with PBT up 65% to ₹1,505 crores and PAT up ~64% to ₹1,127 crores, driven by custom synthesis (~50% YoY growth)

  • H1 FY27 total income rose 28.2% YoY to ₹6,907 crores (vs ₹5,389 crores) and PAT jumped 64.4% to ₹2,029 crores (vs ₹1,234 crores), demonstrating strong operating leverage

  • Custom synthesis now contributes 62% of H1 sales, up from prior periods, with validation batch execution fueling growth, indicating a favorable mix shift toward higher-margin business

  • Nutraceuticals segment grew 16.1% YoY to ₹571 crores from ₹492 crores, adding diversification and incremental revenue

  • Total income from operations grew 13.8% YoY to ₹45,519.9 million in Q2 FY27, showing resilient top-line momentum despite profit decline

  • PBT after exceptional items increased 11.6% YoY to ₹9,996.5 million, suggesting operational profitability before tax remains healthy

  • H1 FY27 EPS of ₹99.97 versus full-year FY26 EPS of ₹192.51 indicates that H1 FY27 already represents ~52% of prior full-year earnings, implying steady annualized performance

  • Generics segment (38% of sales) maintained healthy volumes despite persistent pricing pressure, indicating volume resilience

  • ▲

    RTA office relocation is purely administrative with no financial or operational impact; no action required

Risk Flags (8)

  • Alkem Laboratories↓ [HIGH RISK]
    ▼

    Net profit after tax attributable to owners declined 11.7% YoY to ₹6,753.4 million in Q2 FY27 from ₹7,650.6 million, signaling margin pressure or higher costs

  • Alkem Laboratories↓ [HIGH RISK]
    ▼

    Total comprehensive income attributable to owners fell 17.4% YoY to ₹6,676.4 million from ₹8,083.0 million, indicating broader earnings deterioration beyond net profit

  • Alkem Laboratories↓ [MEDIUM RISK]
    ▼

    EPS dropped to ₹56.48 in Q2 FY27 from ₹63.99 in Q2 FY26, a 11.7% decline, which may pressure stock valuation

  • ▼

    Operating cash flow before taxes halved to ₹959 crores in H1 FY27 despite 50-60% PBT growth, due to working capital locked in a large capex cycle, raising liquidity concerns

  • Divi's Laboratories↓ [MEDIUM RISK]
    ▼

    Finished goods and WIP inventory built up by ₹1,197 crores in H1 FY27, tying up cash and increasing risk of inventory write-downs if demand slows

  • Divi's Laboratories↓ [MEDIUM RISK]
    ▼

    Net forex gain collapsed to ₹20 crores in H1 FY27 from ₹103 crores a year earlier, removing a significant non-operating income cushion

  • Divi's Laboratories↓ [MEDIUM RISK]
    ▼

    Generics segment (38% of sales) continues to face persistent pricing pressure, which could cap margin expansion despite volume growth

  • Sector-wide [LOW RISK]
    ▼

    No insider trading activity disclosed in any of the three filings, limiting visibility into management conviction

Opportunities (6)

  • Divi's Laboratories↓ (OPPORTUNITY)
    ◆

    Custom synthesis growth of ~50% YoY with validation batch execution suggests a strong order book and potential for continued momentum; monitor for capacity expansion announcements

  • Divi's Laboratories↓ (OPPORTUNITY)
    ◆

    Despite cash flow strain, the capex cycle is likely to support future revenue growth; watch for inflection in operating cash flow as projects complete

  • Alkem Laboratories↓ (OPPORTUNITY)
    ◆

    Revenue growth of 13.8% YoY indicates underlying demand strength; if margin pressure is transitory, earnings could rebound, offering a value opportunity

  • Alkem Laboratories↓ (OPPORTUNITY)
    ◆

    PBT growth of 11.6% YoY despite PAT decline suggests tax or below-EBITDA items may be one-off; investigate for potential normalization

  • Divi's Laboratories↓ (OPPORTUNITY)
    ◆

    Nutraceuticals segment growth (16.1% YoY) could be scaled further, providing a diversified revenue stream with potentially higher margins

  • Sector (OPPORTUNITY)
    ◆

    The divergence between Divi's strong growth and Alkem's profit decline may create relative value trades within the pharma index

Sector Themes (5)

  • Divergent Earnings Trajectories
    ◆

    Within the BSE PHARMA index, Divi's Laboratories reported 64% PAT growth while Alkem Laboratories saw an 11.7% PAT decline, highlighting a wide dispersion in earnings performance among pharma companies [IMPLICATION: Stock-specific selection is critical; sector averages mask significant outliers]

  • Working Capital Intensity in Capex Phase
    ◆

    Divi's operating cash flow halved to ₹959 crores due to a ₹1,197 crore inventory build, reflecting a sector-wide theme of companies investing in capacity expansion, which may pressure near-term cash flows [IMPLICATION: Monitor cash flow conversion and capex payback periods]

  • Custom Synthesis as Growth Driver
    ◆

    Divi's custom synthesis segment grew ~50% YoY and now contributes 62% of H1 sales, underscoring the growing importance of CDMO services for Indian pharma companies [IMPLICATION: Companies with strong custom synthesis capabilities may command premium valuations]

  • Pricing Pressure in Generics
    ◆

    Divi's noted persistent pricing pressure in its generics segment (38% of sales), a theme likely affecting other generic-focused pharma companies in the index [IMPLICATION: Focus on companies with differentiated portfolios or limited exposure to commoditized generics]

  • Forex Volatility Impact
    ◆

    Divi's net forex gain fell to ₹20 crores from ₹103 crores, highlighting currency headwinds that could affect other export-oriented pharma companies [IMPLICATION: Hedging strategies and natural hedges become important differentiators]

Watch List (8)

  • Monitor operating cash flow trend in Q3 FY27 for signs of improvement as capex cycle progresses; any further decline could raise liquidity concerns [Watch for quarterly results]

  • Track inventory levels (finished goods and WIP) for potential write-downs if demand slows; current build-up of ₹1,197 crores is significant [Watch for Q3 FY27 inventory disclosures]

  • Watch for margin recovery in Q3 FY27; if PAT decline continues, it may signal structural issues rather than transient pressures [Watch for Q3 FY27 results]

  • Investigate reason for PAT decline despite PBT growth (e.g., tax rate changes, minority interest) for clarity on earnings quality [Watch for analyst call or detailed filings]

  • No financial impact from RTA relocation; however, monitor for any operational disruptions during the transition effective December 1, 2026 [Watch for any subsequent filings]

  • Sector
    👁

    No insider trading activity reported; watch for any Form 4/insider disclosures in the coming weeks for signals of management confidence [Ongoing monitoring]

  • Custom synthesis growth sustainability; watch for new order wins or capacity utilization updates in investor communications [Watch for analyst meets]

  • Revenue growth of 13.8% YoY; watch if this trend accelerates or decelerates in Q3 FY27 for demand signals [Watch for quarterly results]

Filing Analyses (3)
Alkem Laboratories Limited Market Update mixed materiality 4/10

13-11-2026

Alkem Laboratories published a newspaper advertisement on 13 November 2026 disclosing its Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30 September 2026, in compliance with Regulation 30 of SEBI LODR. The filing is a routine procedural intimation with no new financial figures disclosed in the letter itself. The enclosed advertisement page also carries an extract of consolidated results showing Total Income from Operations of ₹45,519.9 million for the quarter ended 30.09.2026 versus ₹40,009.9 million a year earlier, while net profit after tax attributable to owners declined to ₹6,753.4 million from ₹7,650.6 million — a mixed picture of revenue growth alongside profit contraction.

  • · Earnings Per Share (basic and diluted, not annualised): ₹56.48 for Q2 FY27 vs ₹63.99 for Q2 FY26; ₹99.97 for H1 FY27 vs ₹192.51 for full year FY26
  • · Total Comprehensive Income attributable to owners fell 17.4% YoY to ₹6,676.4 Million in Q2 FY27 from ₹8,083.0 Million
  • · Net Profit before tax after exceptional items was ₹9,996.5 Million for Q2 FY27 versus ₹8,958.3 Million a year earlier
  • · Other Equity stood at ₹137,961.9 Million as at 31.03.2026
  • · Advertisement published in The Economic Times (English), Business Standard (English) and Mumbai Lakshadweep (Marathi) on 13 November 2026
  • · Results are unaudited for the quarter and half year ended 30 September 2026; scrip code 539523 (BSE), symbol ALKEM (NSE)
Mankind Pharma Limited Market Update neutral materiality 1/10

13-11-2026

Mankind Pharma disclosed that its Registrar and Share Transfer Agent, KFin Technologies Limited, will relocate its Corporate Office from Nanakramguda, Hyderabad to Kokapet, Telangana effective December 1, 2026. The RTA's Registered Office remains unchanged, and all investor correspondence must be directed to the new address from that date. The filing is a routine administrative intimation under Regulation 30 & 51 with no financial or operational impact on the company.

  • · Scrip Code: 543904; NSE Symbol: MANKIND
  • · Existing RTA Corporate Office: Selenium Building, Tower-B, Plot No. 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Telangana-500032
  • · New RTA Corporate Office (effective December 1, 2026): 6th, 23rd, 24th, 25th Floor, South Tower, Rajapushpa West Avenue, Survey No. 115, Kokapet, Serilingampally Mandal, Ranga Reddy District, Telangana-500075
  • · Filing signed and digitally dated November 13, 2026 at 14:07:05 +05'30'
Divi's Laboratories Limited Analyst/Investor Meet mixed materiality 8/10

13-11-2026

Divi's Laboratories reported Q2 FY27 consolidated total income of ₹3,770 crores versus ₹2,860 crores a year earlier (+32% YoY), with PBT up 65% to ₹1,505 crores and PAT up ~64% to ₹1,127 crores. H1 FY27 total income was ₹6,907 crores (vs ₹5,389 crores), PAT ₹2,029 crores (vs ₹1,234 crores). Growth was driven by custom synthesis (62% of H1 sales, ~50% YoY growth on validation batch execution) while generics (38% of sales) remained stable with healthy volumes but persistent pricing pressure; nutraceuticals rose to ₹571 crores from ₹492 crores. However, net forex gain fell sharply to ₹20 crores from ₹103 crores, and operating cash flow before taxes declined ~50% to ₹959 crores due to working capital locked in a large capex cycle.

  • · Net forex gain fell to ₹20 crores in H1 FY27 from ₹103 crores a year earlier
  • · Operating cash flow before taxes declined ~50% to ₹959 crores despite 50-60% PBT growth, due to working capital in the capex cycle
  • · Finished goods and WIP inventory built up by ₹1,197 crores in H1 FY27
  • · Net material consumption fell to ~32% of sales from 40%, aided by custom synthesis mix and Unit 3 backward integration
  • · Capex guidance of ₹2,000 crores plus or minus 20% per year for the next two to three years
  • · Asset turnover currently about 1.5x for the entire basket
  • · Three dedicated projects: one near commercialization, other two expected in next one or two quarters
  • · Divi's handles 60-70 custom synthesis projects at any given time across phases
  • · Rolling three-month inventory coverage maintained for critical materials
  • · Red Sea/Suez disruptions and elevated petrochemical solvent prices cited as cost headwinds

Get daily alerts with 9 investment signals, 8 risk alerts, 6 opportunities and full AI analysis of all 3 filings

₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: BSE Pharma Sector Regulatory Filings

🇮🇳 More from India

View all →